Syndax Pharmaceuticals Inc. has outlined its strategic position for continued growth, highlighting two exceptional product launches that have surpassed sales expectations. The company targets a $10 billion market opportunity across relapsed/refractory and frontline indications, with two first- and best-in-class medicines addressing significant unmet needs. Notably, the presentation emphasizes the success of Revuforj® (revumenib), the first and only FDA-approved menin inhibitor for treating adult and pediatric patients with relapsed or refractory acute leukemia with a KMT2A translocation. Additionally, Syndax has achieved key milestones, including the submission of a supplemental New Drug Application (sNDA) for relapsed/refractory mNPM1 acute myeloid leukemia $(AML.AU)$ and gaining a listing in clinical guidelines for this indication. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。